Skip to main content
SpringerLink
Log in

Fortschritte nach Jahren des therapeutischen Stillstands

Kleinzelliges Lungenkarzinom: neuer Standard mit Immunchemotherapie

  • Pneumoonkologie
  • Fortbildung
  • Published:
Im Fokus Onkologie Aims and scope

Das kleinzellige Lungenkarzinom (SCLC) ist mit 13–15 % der Lungentumoren eher selten vertreten, die Mehrheit wird als nichtkleinzellige Lungenkarzinome (NSCLC) klassifiziert. Nur bei einem Drittel der SCLC-Erkrankten wird ein potenziell kurativ behandelbares lokalisiertes Stadium diagnostiziert; die meisten SCLC werden allerdings erst im Stadium IV entdeckt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Früh M et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi99–105

    PubMed  Google Scholar 

  2. German Respiratory Society, German Cancer Society, Goeckenjan G et al. Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie. 2011;65(8):e51–e75

    Article  Google Scholar 

  3. Horn L et al. IMpower133 study group: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220

    Article  CAS  Google Scholar 

  4. Reck M et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–8

    Article  CAS  Google Scholar 

  5. Rossi A et al. Carboplatin-orcisplatin-basedchemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(4):1692–8

    Article  CAS  Google Scholar 

  6. Schild SE et al. Small-cell lung cancer in very elderly (≥ 80 years) patients. Clin Lung Cancer. 2019;20(4):313–21

    Article  Google Scholar 

  7. Shirasawa M et al. Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer. PLoS ONE. 2019;14(4):e021459

    Article  Google Scholar 

  8. Slotman B et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–72

    Article  CAS  Google Scholar 

  9. Takahashi T et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–71

    Article  Google Scholar 

  10. Travis et al (Hrsg) (2015) WHO classification of tumours of the lung, pleura, thymus and heart, 4. Aufl.

  11. Turrisi AT III et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–71

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Hämatologie, Onkologie, Pneumologie und Palliativmedizin, Evangelisches Krankenhaus Hamm gGmbH, Werler Straße 110, 59063, Hamm, Deutschland

    Monika Serke

Authors
  1. Monika Serke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Serke.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Serke, M. Kleinzelliges Lungenkarzinom: neuer Standard mit Immunchemotherapie. Im Fokus Onkologie 22, 15–19 (2019). https://doi.org/10.1007/s15015-019-0716-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-019-0716-z

Search

Navigation